#METABOLOMICS WORKBENCH SIMR_Core_Facility_20221214_221037 DATATRACK_ID:3648 STUDY_ID:ST002415 ANALYSIS_ID:AN003936 PROJECT_ID:PR001555
VERSION             	1
CREATED_ON             	December 20, 2022, 11:22 am
#PROJECT
PR:PROJECT_TITLE                 	Proteomics and metabolomics of multiple sclerosis
PR:PROJECT_SUMMARY               	Multiple sclerosis (MS) is a chronic autoimmune disease that affects the
PR:PROJECT_SUMMARY               	myelination of the neurons present in the central nervous system (CNS). The
PR:PROJECT_SUMMARY               	exact etiology of MS development is unclear, but various environmental and
PR:PROJECT_SUMMARY               	genetic factors might play a role in initiating the disease. Current treatments
PR:PROJECT_SUMMARY               	for MS enhance the quality of life and reduce the symptoms. One of these
PR:PROJECT_SUMMARY               	treatments is dimethyl fumarate (DMF), commercially known as Tecfidera.
PR:PROJECT_SUMMARY               	Experimental autoimmune encephalomyelitis (EAE) is a mouse model that is used to
PR:PROJECT_SUMMARY               	study the pathophysiology of MS disease as well as the effects of possible
PR:PROJECT_SUMMARY               	therapeutic agents. In this study, we investigated the effects of SIMR1707 which
PR:PROJECT_SUMMARY               	is a novel compound designed at Sharjah Institute for Medical Research (SIMR). .
PR:PROJECT_SUMMARY               	Single and multiple doses of SIMR1707 demonstrated high safety in mice studies.
PR:PROJECT_SUMMARY               	Treatment of EAE mice with SIMR1707 was able to reduce the EAE clinical scores
PR:PROJECT_SUMMARY               	and maintain their body weight similar to the MS FDA-approved (DMF, Tecfidera),
PR:PROJECT_SUMMARY               	when they were used preventively, prophylactically, or therapeutically. The
PR:PROJECT_SUMMARY               	histological and immunohistochemistry evaluations showed reduced clinical
PR:PROJECT_SUMMARY               	features such as signs of inflammation, demyelination, and infiltration of
PR:PROJECT_SUMMARY               	CD3-positive T cells into the brains of the EAE mice, as compared to
PR:PROJECT_SUMMARY               	vehicle-treated, or untreated EAE mice. Moreover, multi-OMICS experiments
PR:PROJECT_SUMMARY               	including Transcriptomics, Proteomics and Metabolomics were performed to gain
PR:PROJECT_SUMMARY               	insights into the relevant mechanism of action of the SIMR1707 in EAE and thus
PR:PROJECT_SUMMARY               	its therapeutic efficacy to treat MS. Same tissue samples extracted from the
PR:PROJECT_SUMMARY               	cerebellum part of the brain of normal, EAE vehicle-treated, and therapeutic
PR:PROJECT_SUMMARY               	SIMR1707 treated mice, were subjected for the whole RNA-sequencing for
PR:PROJECT_SUMMARY               	transcriptomics, Nano MS for proteomics analysis and LC-MS metabolomics
PR:PROJECT_SUMMARY               	analysis. The multi-OMICs integrative analysis showed that the treatment with
PR:PROJECT_SUMMARY               	SIMR1707 downregulated key biomarkers functionally associated with top pathways
PR:PROJECT_SUMMARY               	including calcium signaling, PI3K/AKT, and mTOR signaling pathways, which may
PR:PROJECT_SUMMARY               	play important roles in EAE and MS pathophysiology. Additionally, the
PR:PROJECT_SUMMARY               	metabolomics-based enriched-for-action pathway analysis showed that the top
PR:PROJECT_SUMMARY               	significantly activated metabolites (FC > 2, p < 0.05) are cholic acid,
PR:PROJECT_SUMMARY               	propionic acid, sphinganine, and nutriacholic acid. Consisting with the
PR:PROJECT_SUMMARY               	functional enrichment pathway analysis, two potent markers, Snta1 and Fscn1,
PR:PROJECT_SUMMARY               	involved in the actin-binding and cytoskeleton are commonly shared between
PR:PROJECT_SUMMARY               	transcriptomics and proteomics and showed mRNA-protein expression correlation in
PR:PROJECT_SUMMARY               	SIMR1707 treated compared to vehicle EAE mice. Importantly, these two markers
PR:PROJECT_SUMMARY               	are involved in the MT2/AKT/GSK3 pathway and may potentially play role in MS and
PR:PROJECT_SUMMARY               	EAE disease
PR:INSTITUTE                     	Sharjah Institute for Medical Research
PR:LAST_NAME                     	Facility
PR:FIRST_NAME                    	Core
PR:ADDRESS                       	M32, SIMR, College of Pharmacy, Health Sciences, University of Sharjah
PR:EMAIL                         	tims-tof@sharjah.ac.ae
PR:PHONE                         	065057656
#STUDY
ST:STUDY_TITLE                   	Proteomics and metabolomics of multiple sclerosis
ST:STUDY_SUMMARY                 	Multiple sclerosis (MS) is a chronic autoimmune disease that affects the
ST:STUDY_SUMMARY                 	myelination of the neurons present in the central nervous system (CNS). The
ST:STUDY_SUMMARY                 	exact etiology of MS development is unclear, but various environmental and
ST:STUDY_SUMMARY                 	genetic factors might play a role in initiating the disease. Current treatments
ST:STUDY_SUMMARY                 	for MS enhance the quality of life and reduce the symptoms. One of these
ST:STUDY_SUMMARY                 	treatments is dimethyl fumarate (DMF), commercially known as Tecfidera.
ST:STUDY_SUMMARY                 	Experimental autoimmune encephalomyelitis (EAE) is a mouse model that is used to
ST:STUDY_SUMMARY                 	study the pathophysiology of MS disease as well as the effects of possible
ST:STUDY_SUMMARY                 	therapeutic agents. In this study, we investigated the effects of SIMR1707 which
ST:STUDY_SUMMARY                 	is a novel compound designed at Sharjah Institute for Medical Research (SIMR). .
ST:STUDY_SUMMARY                 	Single and multiple doses of SIMR1707 demonstrated high safety in mice studies.
ST:STUDY_SUMMARY                 	Treatment of EAE mice with SIMR1707 was able to reduce the EAE clinical scores
ST:STUDY_SUMMARY                 	and maintain their body weight similar to the MS FDA-approved (DMF, Tecfidera),
ST:STUDY_SUMMARY                 	when they were used preventively, prophylactically, or therapeutically. The
ST:STUDY_SUMMARY                 	histological and immunohistochemistry evaluations showed reduced clinical
ST:STUDY_SUMMARY                 	features such as signs of inflammation, demyelination, and infiltration of
ST:STUDY_SUMMARY                 	CD3-positive T cells into the brains of the EAE mice, as compared to
ST:STUDY_SUMMARY                 	vehicle-treated, or untreated EAE mice. Moreover, multi-OMICS experiments
ST:STUDY_SUMMARY                 	including Transcriptomics, Proteomics and Metabolomics were performed to gain
ST:STUDY_SUMMARY                 	insights into the relevant mechanism of action of the SIMR1707 in EAE and thus
ST:STUDY_SUMMARY                 	its therapeutic efficacy to treat MS. Same tissue samples extracted from the
ST:STUDY_SUMMARY                 	cerebellum part of the brain of normal, EAE vehicle-treated, and therapeutic
ST:STUDY_SUMMARY                 	SIMR1707 treated mice, were subjected for the whole RNA-sequencing for
ST:STUDY_SUMMARY                 	transcriptomics, Nano MS for proteomics analysis and LC-MS metabolomics
ST:STUDY_SUMMARY                 	analysis. The multi-OMICs integrative analysis showed that the treatment with
ST:STUDY_SUMMARY                 	SIMR1707 downregulated key biomarkers functionally associated with top pathways
ST:STUDY_SUMMARY                 	including calcium signaling, PI3K/AKT, and mTOR signaling pathways, which may
ST:STUDY_SUMMARY                 	play important roles in EAE and MS pathophysiology. Additionally, the
ST:STUDY_SUMMARY                 	metabolomics-based enriched-for-action pathway analysis showed that the top
ST:STUDY_SUMMARY                 	significantly activated metabolites (FC > 2, p < 0.05) are cholic acid,
ST:STUDY_SUMMARY                 	propionic acid, sphinganine, and nutriacholic acid. Consisting with the
ST:STUDY_SUMMARY                 	functional enrichment pathway analysis, two potent markers, Snta1 and Fscn1,
ST:STUDY_SUMMARY                 	involved in the actin-binding and cytoskeleton are commonly shared between
ST:STUDY_SUMMARY                 	transcriptomics and proteomics and showed mRNA-protein expression correlation in
ST:STUDY_SUMMARY                 	SIMR1707 treated compared to vehicle EAE mice. Importantly, these two markers
ST:STUDY_SUMMARY                 	are involved in the MT2/AKT/GSK3 pathway and may potentially play role in MS and
ST:STUDY_SUMMARY                 	EAE disease
ST:INSTITUTE                     	Sharjah Institute for Medical Research
ST:LAST_NAME                     	Facility
ST:FIRST_NAME                    	Core
ST:ADDRESS                       	M32, SIMR, College of Pharmacy, Health Sciences, University of Sharjah
ST:EMAIL                         	tims-tof@sharjah.ac.ae
ST:PHONE                         	065057656
#SUBJECT
SU:SUBJECT_TYPE                  	Mammal
SU:SUBJECT_SPECIES               	Mus musculus
SU:TAXONOMY_ID                   	10090
#SUBJECT_SAMPLE_FACTORS:         	SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Raw file names and additional sample data
SUBJECT_SAMPLE_FACTORS           	-	1TH1707 M1-01_10_1_3408	Group:Therapeutic	RAW_FILE_NAME=TH1707 M1-01_10_1_3408.d
SUBJECT_SAMPLE_FACTORS           	-	TH1707 M1-02_10_1_3409	Group:Therapeutic	RAW_FILE_NAME=TH1707 M1-02_10_1_3409.d
SUBJECT_SAMPLE_FACTORS           	-	TH1707 M2-01_11_1_3410	Group:Therapeutic	RAW_FILE_NAME=TH1707 M2-01_11_1_3410.d
SUBJECT_SAMPLE_FACTORS           	-	TH1707 M2-02_11_1_3411	Group:Therapeutic	RAW_FILE_NAME=TH1707 M2-02_11_1_3411.d
SUBJECT_SAMPLE_FACTORS           	-	TH1707 M3-01_12_1_3412	Group:Therapeutic	RAW_FILE_NAME=TH1707 M3-01_12_1_3412.d
SUBJECT_SAMPLE_FACTORS           	-	TH1707 M3-02_12_1_3413	Group:Therapeutic	RAW_FILE_NAME=TH1707 M3-02_12_1_3413.d
SUBJECT_SAMPLE_FACTORS           	-	TH1707 M4-01_13_1_3414	Group:Therapeutic	RAW_FILE_NAME=TH1707 M4-01_13_1_3414.d
SUBJECT_SAMPLE_FACTORS           	-	TH1707 M4-02_13_1_3415	Group:Therapeutic	RAW_FILE_NAME=TH1707 M4-02_13_1_3415.d
SUBJECT_SAMPLE_FACTORS           	-	VehicleEAE M1-01_7_1_3402	Group:Vehicle	RAW_FILE_NAME=VehicleEAE M1-01_7_1_3402.d
SUBJECT_SAMPLE_FACTORS           	-	VehicleEAE M1-02_7_1_3403	Group:Vehicle	RAW_FILE_NAME=VehicleEAE M1-02_7_1_3403.d
SUBJECT_SAMPLE_FACTORS           	-	VehicleEAE M2-01_8_1_3404	Group:Vehicle	RAW_FILE_NAME=VehicleEAE M2-01_8_1_3404.d
SUBJECT_SAMPLE_FACTORS           	-	VehicleEAE M2-02_8_1_3405	Group:Vehicle	RAW_FILE_NAME=VehicleEAE M2-02_8_1_3405.d
SUBJECT_SAMPLE_FACTORS           	-	VehicleEAE M3-01_9_1_3406	Group:Vehicle	RAW_FILE_NAME=VehicleEAE M3-01_9_1_3406.d
SUBJECT_SAMPLE_FACTORS           	-	VehicleEAE M3-02_9_1_3407	Group:Vehicle	RAW_FILE_NAME=VehicleEAE M3-02_9_1_3407.d
#COLLECTION
CO:COLLECTION_SUMMARY            	The experiments on the mice were approved by the University of Sharjah animal
CO:COLLECTION_SUMMARY            	care and use committee (ACUC) (ACUC approval number: ACUC-16-003-EAE and
CO:COLLECTION_SUMMARY            	ACUC-21-09-06-01). The mice were housed at the University of Sharjah animal
CO:COLLECTION_SUMMARY            	facility, in plastic cages under a controlled environment of 24 ± 2 °C, 50% ±
CO:COLLECTION_SUMMARY            	5% humidity, 12 h/12 h light-dark cycle with unlimited food and water access.
CO:SAMPLE_TYPE                   	Brain
#TREATMENT
TR:TREATMENT_SUMMARY             	From Normal, EAE vehicle-treated, and therapeutic SIMR1707 treated mice, the
TR:TREATMENT_SUMMARY             	cerebellum part of the brain was cut, and immediately snap frozen using liquid
TR:TREATMENT_SUMMARY             	nitrogen. The samples then were weighed, made in powder form and homogenized
TR:TREATMENT_SUMMARY             	using pistol method under liquid nitrogen. The cerebellum sample was lysed using
TR:TREATMENT_SUMMARY             	400 uL RIBA lysis buffer and let to set for 5-10 minutes to allow lysis. 50 ul
TR:TREATMENT_SUMMARY             	of the homogenized sample was taken for RNA extraction using norgen biotek
TR:TREATMENT_SUMMARY             	RNA/DNA purification kit (cat#:47700) according to the manufacturer’s
TR:TREATMENT_SUMMARY             	instructions. The remaining 350 uL was processed for metabolites and proteins
TR:TREATMENT_SUMMARY             	extraction. First, it was centrifuged for 5 minutes at 4 C, 13000 rpm. The
TR:TREATMENT_SUMMARY             	supernatant was collected in a new 1.5 mL eppendorf tube. The supernatant was
TR:TREATMENT_SUMMARY             	centrifuged again for 1 minute at 4 C, at maximum speed (>13000 rpm), and the
TR:TREATMENT_SUMMARY             	supernatant was collected again in a new 1.5 mL tube and kept on ice as it was
TR:TREATMENT_SUMMARY             	used in the following steps, while the pellet was discarded.
#SAMPLEPREP
SP:SAMPLEPREP_SUMMARY            	400 uL of methanol, and 300 uL of chloroform were added to the protein sample,
SP:SAMPLEPREP_SUMMARY            	and centrifuged for 5 minutes, at 4 C, 13000 rpm. Three phases appeared: the
SP:SAMPLEPREP_SUMMARY            	upper phase is the metabolites, the middle is the protein, and the lower phase
SP:SAMPLEPREP_SUMMARY            	is other metabolites. The metabolites' upper phase was kept in a new eppendorf
SP:SAMPLEPREP_SUMMARY            	tube and kept at -20 C. 300 uL methanol was added to the middle and the lower
SP:SAMPLEPREP_SUMMARY            	phases then they were mixed and centrifuged for 1 minute at 13000 rpm. The
SP:SAMPLEPREP_SUMMARY            	supernatant was added to the metabolite tube and then it was kept at - 80C for
SP:SAMPLEPREP_SUMMARY            	longer storage.
#CHROMATOGRAPHY
CH:CHROMATOGRAPHY_TYPE           	Reversed phase
CH:INSTRUMENT_NAME               	Bruker Elute
CH:COLUMN_NAME                   	Hamilton Intensity Solo 2 C18(100 x 2.1 mm, 1.8 um)
CH:SOLVENT_A                     	100% water; 0.1% formic acid
CH:SOLVENT_B                     	100% acetonitrile; 0.1% formic acid
CH:FLOW_GRADIENT                 	1%B to 99%B in 15 min
CH:FLOW_RATE                     	250 uL/min
CH:COLUMN_TEMPERATURE            	35
#ANALYSIS
AN:ANALYSIS_TYPE                 	MS
#MS
MS:INSTRUMENT_NAME               	Bruker timsTOF
MS:INSTRUMENT_TYPE               	QTOF
MS:MS_TYPE                       	ESI
MS:ION_MODE                      	POSITIVE
MS:MS_COMMENTS                   	Metabolomics Data Processing. For metabolomic analysis, MetaboScape® 4.0
MS:MS_COMMENTS                   	program (Bruker Daltonics, Billerica, MA, USA) was employed for data processing,
MS:MS_COMMENTS                   	feature extrac-tion and metabolite identification. The T-ReX 2D/3D workflow was
MS:MS_COMMENTS                   	used to identify the molecular features with the following settings: The minimum
MS:MS_COMMENTS                   	peak length was set to 7 spectra and the minimum intensity threshold was 1000
MS:MS_COMMENTS                   	counts for peaks detection. The peak area was employed for quantification and
MS:MS_COMMENTS                   	the injected external calibrant in the in-terval of 0–0.3 min was used to
MS:MS_COMMENTS                   	recalibrate the mass spectra. The selected mass to charge ratio (m/z) and
MS:MS_COMMENTS                   	retention time for scanning were in the ranges of 20–1300 m/z and 0.3–30
MS:MS_COMMENTS                   	min, respectively. MS/MS spectra for features were averaged on import and
MS:MS_COMMENTS                   	features found at least in 12 of the 40 injections were taken into further
MS:MS_COMMENTS                   	consideration. Metabolites were identified by matching to the human metabolome
MS:MS_COMMENTS                   	database (HMDB) by combined MS/MS, precursor m/z values, and isotopic pattern
MS:MS_COMMENTS                   	scores. Where multiple features matched a given database entry, the annotation
MS:MS_COMMENTS                   	quality score (AQ score) was used to select only the best matching feature.
#MS_METABOLITE_DATA
MS_METABOLITE_DATA:UNITS	AU
MS_METABOLITE_DATA_START
Samples	TH1707 M1-02_10_1_3409	TH1707 M2-01_11_1_3410	TH1707 M2-02_11_1_3411	TH1707 M3-01_12_1_3412	TH1707 M3-02_12_1_3413	TH1707 M4-01_13_1_3414	TH1707 M4-02_13_1_3415	VehicleEAE M1-01_7_1_3402	VehicleEAE M1-02_7_1_3403	VehicleEAE M2-01_8_1_3404	VehicleEAE M2-02_8_1_3405	VehicleEAE M3-01_9_1_3406	VehicleEAE M3-02_9_1_3407
Factors	Group:Therapeutic	Group:Therapeutic	Group:Therapeutic	Group:Therapeutic	Group:Therapeutic	Group:Therapeutic	Group:Therapeutic	Group:Vehicle	Group:Vehicle	Group:Vehicle	Group:Vehicle	Group:Vehicle	Group:Vehicle
2,2-Dimethylsuccinic acid	9280	7100	7322	7486	7304	8512	8144	9486	9026	8682	7268	8886	9216
2-Hydroxycaproic acid	111688	87318	77618	81168	82904	89782	91432	80916	97558	93550	93408	60356	56478
2-Ketobutyric acid	39524	32112	35002	31520	34290	36650	40080	42678	38236	32538	31838	39992	38938
2-Ketohexanoic acid	8510	8146	8652	6092	6090	11126	0	5810	7304	7896	7656	0	0
2-Phenylbutyric acid	53310	54302	53826	42400	48072	50598	44770	52792	51782	51618	51368	1604	1550
2-Pyrrolidinone	2830	3898	3218	4340	3534	2566	2284	2860	3286	3872	4818	6388	6812
3,4-Dihydroxyphenylglycol	16948	16566	18202	15378	14930	16806	17010	13430	14232	16320	13618	13910	14322
3-Aminoisobutanoic acid	44826	39362	36368	31670	31038	46420	41526	53474	54532	45412	41196	34120	43346
3-Hexenedioic acid	3020	1670	2046	2790	2856	4194	3800	3128	2994	3524	3874	3448	3432
3b-Hydroxy-5-cholenoic acid	74716	72372	74956	75052	74972	72318	77058	71448	70746	69732	75760	16602	18510
5'-Methylthioadenosine	64062	52308	58022	77044	75194	73216	70898	53600	53128	41452	44564	70282	67364
Acrylamide	378462	692310	699450	737722	708144	738288	735246	733834	727676	661846	678372	762818	735206
Adenine	482192	201998	196652	597668	587756	0	0	577874	574206	367278	355148	770412	9272
Adenosine monophosphate	125264	80392	81030	138264	140928	149544	154802	0	142184	129648	132450	81270	79794
Adenylsuccinic acid	85180	12876	13476	71996	71464	89222	85466	65382	71040	68728	66064	16500	15058
ADP	9226	1792	1754	3418	2774	8070	8926	7744	9152	7050	7028	2164	1656
Benzocaine	63444	47098	42948	70492	71650	72168	75034	70936	69758	53860	48924	76240	72124
Cadaverine	2856	3426	3128	4172	3890	4674	4108	3654	3914	4208	3776	1910	2180
Caffeine	451178	343164	362312	358250	337984	357264	375800	316646	315902	316526	331694	177410	164052
Cholic acid	5902	2330	0	242	358	0	0	21166	20168	24052	1374	0	0
Cinnamic acid	4046	3626	3280	6896	5238	6876	5482	4992	5458	3958	3762	4830	6088
Creatine	93862	71728	71182	114928	115752	107644	107784	97496	98144	88314	88404	103030	105438
Cyclic AMP	2970	1296	1062	2328	2528	2718	2976	3106	2398	2510	2416	1710	1650
Cytidine	2060	1482	0	2304	2364	2140	2194	2564	2168	1696	1716	2936	2852
D-Alanine	40440	30124	29912	51268	49428	51020	48204	41024	46700	34902	34614	46068	44534
Diacetyl	37768	33482	32662	35052	30178	36712	46244	33926	35060	33368	31308	34364	34572
Glutathione	114786	30420	30758	90692	90754	99218	113800	103738	109102	86728	86962	83638	84738
Glycerol	23662	19880	22440	33026	22752	28662	19638	21368	20456	24246	27954	22478	18426
Glycerophosphocholine	22122	16024	15310	24104	22876	21380	22302	18008	17474	16812	16586	16930	16096
Guaifenesin	11424	7798	9912	10400	9910	8750	11038	5782	5252	5580	6872	10618	7088
Guanine	79466	77002	71648	110138	117944	98256	97046	125446	120512	88020	88662	173098	181246
Guanosine	60520	54358	52872	87090	87720	70446	68514	88212	81856	66090	62666	124920	131704
Guanosine 5'-diphosphate	12520	6106	6000	5000	4972	8000	8192	7628	8550	6344	6944	5486	4334
Guanosine monophosphate	19218	14782	15714	32506	31726	26116	27012	0	27230	23686	23024	27794	25682
Hyodeoxycholic acid	40544	20862	20834	10166	10190	20716	9662	22992	2374	25740	29904	2802	2562
Hypoxanthine	567314	644958	636882	725226	726094	699424	666380	738324	731124	634648	637646	739490	763420
Indole	6430	5456	4420	8120	8782	6928	7030	0	6570	4508	4646	8720	7184
Indoleacrylic acid	118188	100112	96894	156606	152826	139976	129226	109872	109374	91618	91528	147588	141986
Inosine	156374	200234	191136	272244	257928	220740	208310	271120	261938	206876	199744	298234	297036
Isobutyric acid	219072	188734	185696	174322	166516	181006	200248	230576	223228	194792	198904	141654	150942
Isovalerylcarnitine	9412	7048	8214	17648	17300	12956	13212	10110	9832	20640	20458	18524	14966
L(-)-Nicotine pestanal	2924	3390	2728	4862	3718	2784	3118	3338	3852	3008	3198	2524	2598
L-Acetylcarnitine	64086	38850	37004	49956	50350	82554	87436	66746	66258	75270	71664	67730	67356
L-Aspartic acid	18546	14192	14212	24512	23900	0	0	20666	21040	18390	17544	24172	23846
L-Carnitine	17924	17078	16718	26362	25724	23276	24722	19178	20584	23286	22386	25584	27730
L-Glutamic acid	33008	30618	31526	54756	47402	50216	51704	26434	0	32138	32942	32690	31454
L-Norleucine	3206	2504	1892	3104	2992	3378	2582	3300	3512	3294	2936	4868	4966
L-Tryptophan	29828	20220	18666	35334	34684	31204	30262	33670	27944	20006	23184	35442	37310
m-Coumaric acid	5332	3088	3674	5572	6778	4546	3824	5544	7216	2464	2830	7956	8376
Maltitol	10774	11456	11512	11632	11668	11628	12550	13202	11796	10998	11148	11308	10922
Medroxyprogesterone	22884	9914	11132	10146	11582	8298	5430	21584	24686	24884	20088	0	714
Methylhippuric acid	5420	6544	5200	5834	5004	5142	5784	5560	5998	4826	4854	5452	5450
N,N-Dimethylformamide	16370	31800	40030	83044	64572	0	85068	18406	16652	14294	10734	49194	90688
N-Acetyl-L-alanine	3112	2880	2982	3018	3390	2956	2938	2738	2598	2726	2852	3256	3136
N-Acetyl-L-aspartic acid	15820	11910	11558	18766	18560	17180	18860	15504	17030	15520	15076	0	20648
Niacinamide	13482	1832	1546	5098	4812	10840	12892	10316	12374	10740	10280	2712	3062
Normetanephrine	5302	4984	4978	6386	6458	5956	6200	6136	6976	4378	4408	6956	8110
Nutriacholic acid	35938	32514	34768	21236	19836	44984	33708	15988	16446	22554	21362	676	616
o-Tyrosine	5918	5222	4438	6786	8618	6782	6896	7026	7800	2912	3412	9920	10632
Pantothenic acid	93470	73722	71698	115524	104324	97210	96844	98356	107834	71872	73616	121604	123984
Phenylacetaldehyde	80258	92648	87680	87298	77218	83270	62748	90364	89934	91462	85668	0	1732
Phenylacetic acid	1886	2114	2646	1822	2076	1952	1600	2616	2442	2988	2638	2178	2480
Phosphocreatine	3582	3098	3102	0	0	0	0	3218	3138	0	0	0	0
Phosphoric acid	6274	3854	4430	5956	5892	5266	4856	5706	6030	4906	5826	7402	6508
Propionic acid	5638	4330	5176	2856	6078	7054	5948	484	1570	2424	2930	3402	4446
Propylene glycol	20648	19172	19170	20252	19594	20124	25912	20912	20568	17088	18884	20952	20668
Pyridine	19722	11872	11574	16958	22634	19892	16024	25032	24344	14562	22908	14016	24316
Pyroglutamic acid	145388	96222	93390	161960	157810	130444	164906	136462	160222	115092	111312	151680	157514
Rhamnose	4494	4972	5184	4476	4456	5524	5394	4480	4216	4234	3736	4948	3980
S-Adenosylhomocysteine	11808	13568	13098	18128	17186	17908	17504	19538	17344	11896	11866	22058	20970
Saccharopine	2426	5410	7270	4184	5994	4310	4682	2768	2870	2346	5446	5636	5356
Sorbitol	11768	12782	13154	11884	12296	12584	12788	11272	11450	11984	11844	12160	12154
Spermine	27558	16398	16602	17368	18542	24190	20172	24706	23826	16240	16720	7010	6368
Sphinganine	27664	20910	0	18334	13516	24890	0	16182	13622	13272	12426	306	328
Sphingosine	5448	9670	6654	8648	9222	5966	3786	5328	5800	5594	5578	1020	948
Succinic acid	14392	17662	17528	18870	19386	15010	14604	19552	20358	9848	9968	31156	30402
Uracil	5652	4322	4998	8252	7508	7790	8352	4718	5752	4628	4540	5970	4482
Urea	3298	2692	3644	3074	3460	2952	2816	2076	3040	3070	2944	2448	2798
Uridine	3682	3076	3152	5120	4026	4434	4912	2232	3132	2456	2462	3338	3304
Valeric acid	3300	2350	2622	3542	2974	3512	4682	3026	3366	2846	2794	3358	3756
MS_METABOLITE_DATA_END
#METABOLITES
METABOLITES_START
metabolite_name	RT [min]	m/z meas.	M meas.	Ions
2,2-Dimethylsuccinic acid	8.68	147.06514	146.05787	[M+H]+
2-Hydroxycaproic acid	10.36	133.08632	132.07904	[M+H]+
2-Ketobutyric acid	8.9	103.03923	102.03195	[M+H]+
2-Ketohexanoic acid	16.09	131.07092	130.06365	[M+H]+
2-Phenylbutyric acid	17.22	165.09138	164.0841	[M+H]+
2-Pyrrolidinone	19.79	86.06019	85.05291	[M+H]+
3,4-Dihydroxyphenylglycol	7.39	171.06282	170.05555	[M+H]+
3-Aminoisobutanoic acid	10.15	104.07095	103.06368	[M+H]+
3-Hexenedioic acid	3.79	145.04948	144.04221	[M+H]+
3b-Hydroxy-5-cholenoic acid	16.43	375.2898	374.28252	[M+H]+
5'-Methylthioadenosine	8.55	298.09695	297.08968	[M+H]+
Acrylamide	9.22	72.04433	71.03706	[M+H]+
Adenine	7.67	136.06165	135.05438	[M+H]+
Adenosine monophosphate	4.26	348.07029	347.06301	[M+H]+
Adenylsuccinic acid	8.03	464.08134	463.07406	[M+H]+
ADP	7.4	428.03672	427.02944	[M+H]+
Benzocaine	8.16	166.08629	165.07901	[M+H]+
Cadaverine	10.73	103.12333	102.11605	[M+H]+
Caffeine	9.25	195.0876	194.08033	[M+H]+
Cholic acid	20.92	409.2928	408.28553	[M+H]+
Cinnamic acid	8.16	149.05978	148.0525	[M+H]+
Creatine	3.07	132.07671	131.06944	[M+H]+
Cyclic AMP	7.82	330.06	329.05273	[M+H]+
Cytidine	3.81	244.09285	243.08557	[M+H]+
D-Alanine	3.04	90.05504	89.04777	[M+H]+
Diacetyl	8.4	87.04427	86.037	[M+H]+
Glutathione	4.07	308.09108	307.08381	[M+H]+
Glycerol	3.32	93.0548	92.04753	[M+H]+
Glycerophosphocholine	3.46	258.11018	257.1029	[M+H]+
Guaifenesin	9.68	199.09434	198.08706	[M+H]+
Guanine	7.8	152.05668	151.04941	[M+H]+
Guanosine	7.8	284.099	283.09173	[M+H]+
Guanosine 5'-diphosphate	7.39	444.03169	443.02442	[M+H]+
Guanosine monophosphate	4.87	364.0653	363.05802	[M+H]+
Hyodeoxycholic acid	21.59	393.29808	392.29081	[M+H]+
Hypoxanthine	7.82	137.04567	136.03843	[M+H]+, [M-H2O+H]+
Indole	8.7	118.06523	117.05796	[M+H]+
Indoleacrylic acid	8.71	188.07068	187.0634	[M+H]+
Inosine	7.81	269.08799	268.08072	[M+H]+
Isobutyric acid	10.07	89.05968	88.0524	[M+H]+
Isovalerylcarnitine	8.94	246.17011	245.16283	[M+H]+
L(-)-Nicotine pestanal	7.38	163.12304	162.11577	[M+H]+
L-Acetylcarnitine	3.8	204.12307	203.1158	[M+H]+
L-Aspartic acid	4.02	134.04475	133.03747	[M+H]+
L-Carnitine	3.02	162.11253	161.10525	[M+H]+
L-Glutamic acid	7.41	148.06042	147.05314	[M+H]+
L-Norleucine	5.65	132.10194	131.09467	[M+H]+
L-Tryptophan	8.7	205.09729	204.09002	[M+H]+
m-Coumaric acid	6	165.05473	164.04746	[M+H]+
Maltitol	3.8	345.13921	344.13193	[M+H]+
Medroxyprogesterone	19.92	345.24047	344.23319	[M+H]+
Methylhippuric acid	8.21	194.07885	193.07157	[M+H]+
N,N-Dimethylformamide	7.3	74.06014	73.05286	[M+H]+
N-Acetyl-L-alanine	22.51	132.06557	131.05829	[M+H]+
N-Acetyl-L-aspartic acid	4.06	176.05543	175.04815	[M+H]+
Niacinamide	7.4	123.05537	122.04809	[M+H]+
Normetanephrine	8.41	184.09692	183.08964	[M+H]+
Nutriacholic acid	15.52	391.28466	390.27738	[M+H]+
o-Tyrosine	6.08	182.0813	181.07403	[M+H]+
Pantothenic acid	8.4	220.1181	219.11083	[M+H]+
Phenylacetaldehyde	17.23	121.06536	120.05809	[M+H]+
Phenylacetic acid	12.84	137.05978	136.05251	[M+H]+
Phosphocreatine	3.66	212.04314	211.03587	[M+H]+
Phosphoric acid	3.57	98.98443	97.97715	[M+H]+
Propionic acid	0.31	75.04424	74.03697	[M+H]+
Propylene glycol	8.4	77.05979	76.05251	[M+H]+
Pyridine	4.32	80.0496	79.04232	[M+H]+
Pyroglutamic acid	7.5	130.04987	129.04259	[M+H]+
Rhamnose	7.92	165.07585	164.06714	[M+H]+, [M+K]+
S-Adenosylhomocysteine	7.51	385.12898	384.12119	[M+H]+, [M+H+H]2+
Saccharopine	14.56	277.1413	276.13402	[M+H]+
Sorbitol	3.75	183.08641	182.07913	[M+H]+
Spermine	1.91	203.22315	202.21587	[M+H]+
Sphinganine	13.65	302.30557	301.29829	[M+H]+
Sphingosine	19.63	300.29019	299.2829	[M+H]+, [M+Na]+
Succinic acid	7.69	119.03529	118.02801	[M+H]+
Uracil	7.43	113.03449	112.02721	[M+H]+
Urea	22.81	61.03975	60.03248	[M+H]+
Uridine	7.37	245.07682	244.06955	[M+H]+
Valeric acid	8.39	103.07568	102.06841	[M+H]+
METABOLITES_END
#END